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The endocannabinoid system comprises several molecular entities such as endogenous
ligands [anandamide (AEA) and 2-arachidonoylglycerol (2-AG)], receptors (CB1 and
CB2), enzymes such as [fatty acid amide hydrolase (FAHH) and monoacylglycerol lipase
(MAGL)], as well as the anandamide membrane transporter. Although the role of this
complex neurobiological system in the sleep–wake cycle modulation has been studied,
the contribution of the blocker of FAAH/transient receptor potential cation channel
subfamily V member 1 (TRPV1), N-arachidonoyl-serotonin (AA-5-HT) in sleep has not
been investigated. Thus, in the present study, varying doses of AA-5-HT (5, 10, or
20 mg/Kg, i.p.) injected at the beginning of the lights-on period of rats, caused no
statistical changes in sleep patterns. However, similar pharmacological treatment given
to animals at the beginning of the dark period decreased wakefulness (W) and increased
slow wave sleep (SWS) as well as rapid eye movement sleep (REMS). Power spectra
analysis of states of vigilance showed that injection of AA-5-HT during the lights-off
period diminished alpha spectrum across alertness in a dose-dependent fashion. In
opposition, delta power spectra was enhanced as well as theta spectrum, during
SWS and REMS, respectively. Moreover, the highest dose of AA-5-HT decreased
wake-related contents of neurotransmitters such as dopamine (DA), norepinephrine
(NE), epinephrine (EP), serotonin (5-HT) whereas the levels of adenosine (AD) were
enhanced. In addition, the sleep-inducing properties of AA-5-HT were confirmed since
this compound blocked the increase in W caused by stimulants such as cannabidiol
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(CBD) or modafinil (MOD) during the lights-on period. Additionally, administration of
AA-5-HT also prevented the enhancement in contents of DA, NE, EP, 5-HT and AD
after CBD of MOD injection. Lastly, the role of AA-5-HT in sleep homeostasis was tested
in animals that received either CBD or MOD after total sleep deprivation (TSD). The
injection of CBD or MOD increased alertness during sleep rebound period after TSD.
However, AA-5-HT blocked this effect by allowing animals to display an enhancement in
sleep across sleep rebound period. Overall, our findings provide evidence that AA-5-HT
is an important modulator of sleep, sleep homeostasis and neurotransmitter contents.
Keywords: sleep, dopamine, modafinil, cannabidiol, sleep deprivation
INTRODUCTION
The endocannabinoid system is a complex biological
arrangement that exerts multiple modulatory functions (Kendall
and Yudowski, 2016; Ligresti et al., 2016; Argueta and DiPatrizio,
2017; Bennett et al., 2017; Dos Anjos-Garcia et al., 2017; Sun
et al., 2017). The components of the endocannabinoid system
include the most studied endocannabinoids anandamide (AEA)
and 2-arachidonoylglycerol (2-AG; Di Marzo and Piscitelli,
2015; Yuan et al., 2016; Biernacki and Skrzydlewska, 2016;
Correa et al., 2016; Huang et al., 2016; Lu and Mackie, 2016;
Fakhoury, 2017). The endocannabinoids bind to transmembrane
proteins denominated CB1 and CB2 cannabinoid receptors
(Kendall and Yudowski, 2016; Kruk-Slomka et al., 2016; Chen
et al., 2017; Fitzpatrick and Downer, 2017; Mallipeddi et al.,
2017). Additionally, it has been reported that the main enzymes
responsible for the hydrolysis of AEA and 2-AG are fatty acid
amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL),
respectively (Piomelli, 2014; Biernacki and Skrzydlewska, 2016;
Janssen and van der Stelt, 2016). Lastly, several pieces of evidence
have shown that anandamide membrane transporter (AMT)
also displays a key role in modulating multiple biological
functions (Leung et al., 2013; Nicolussi and Gertsch, 2015).
Among the diverse findings that suggest the involvement of the
endocannabinoid system in regulating several neurobiological
phenomena, different reports have indicated that the sleep-wake
cycle is likely under control of this system (Santucci et al., 1996;
Murillo-Rodríguez et al., 1998, 2001, 2003, 2008a, 2011a, 2013,
2016; Herrera-Solis et al., 2010; Rueda-Orozco et al., 2010;
Pava et al., 2014, 2016). Due to recent results regarding the
relationship between AEA and the transient receptor potential
cation channel subfamily V member 1 (TRPV1) also known
as the capsaicin receptor or vanilloid receptor 1, increasing
scientific interest is addressing the neuromolecular properties of
TRPV1 (Tóth et al., 2009; Lowin and Straub, 2015; Chen et al.,
2016; Kirkedal et al., 2016). An experimental approach aimed
to describe the neuromolecular role of TRPV1 has included
pharmacological means by using N-arachidonoylserotonin
(AA-5-HT). For example, it has been reported that this drug
is a dual blocker at FAAH/TRPV1 inducing anxiolytic-like
effects in mice (Micale et al., 2009). Moreover, different doses
of AA-5-HT (0–0.5 nmol) administered into the basolateral
amygdala prior to elevated plus maze testing increased time
spent into the open arms (John and Currie, 2012). In addition,
it has been shown that AA-5-HT induces anticonvulsant effects
(Micale et al., 2009; Vilela et al., 2014), reduces depression-
like behavior (Navarria et al., 2014; Kirkedal et al., 2016) and
promotes recovery from stress (Sartim et al., 2017). Despite this
accumulating body of evidence regarding the neurobiological
role of AA-5-HT, no evidence is available on whether this
compound might modulate the sleep-wake cycle. Thus, we
investigated the effects of AA-5-HT (5, 10, 20 mg/Kg, i.p.) on
sleep as well as extracellular contents of neurotransmitters linked
to the sleep-wake cycle such as dopamine (DA), norepinephrine
(NE), epinephrine (EP), serotonin (5-HT), as well as adenosine
(AD). Moreover, to provide further evidence regarding the
putative sleep-inducing properties of AA-5-HT, we tested
whether this drug would block the alertness caused by the
phytocannabinoid cannabidiol (CBD, 30 mg/Kg, ip; Murillo-
Rodríguez et al., 2006, 2008b, 2011b; Kim, 2012) or the stimulant
drug modafinil (MOD, 30 mg/Kg, i.p.; Sukhal et al., 2015;
Wang et al., 2015; Barateau et al., 2016). In addition, the role
of AA-5-HT in sleep homeostasis was addressed in CBD- or
MOD-treated animals that were sleep deprived. Our study
provides novel findings about the possible role of AA-5-HT in
sleep modulation.
MATERIALS AND METHODS
Experiment 1: Effects on Sleep after
Injections of AA-5-HT during Either the
Lights-On or Lights-Off Period
Experimental Animals
Male Wistar rats (n = 50; 250–300 g) were singly housed
in polycarbonate cages (48.26 cm × 26.67 cm × 20.32 cm;
Harlan Laboratories. México) under light-dark cycle (lights-on:
07:00–19:00h), humidity controlled (60 ± 10%) and constant
temperature (21± 1◦C). Rats had free access to Purina Rat Chow
(Purina. México) as well as tap water. The experimental protocols
were approved by the Research and Ethics Committee of our
University fulfilling the domestic and international standards
of animal welfare including the Mexican Standards Related to
Use and Management of Laboratory Animals (DOF. NOM-062-
Z00-1999) as well as the National Institutes of Health (NIH
publication No. 80–23, revised 1996). During the whole study,
efforts to minimize animal suffering were considered and for
ethical reasons, a reduced number of animals was used.
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Chemicals
AA-5-HT was provided by Prof. Vincenzo Di Marzo and
chemical was dissolved in a vehicle (VEH) solution composed
of polyethylene-glycol/saline (5:95 v/v) as described previously
(Murillo-Rodríguez et al., 2003, 2011a, 2013). All reagents,
chemicals, and materials were purchased from Sigma–Aldrich
(St Louis, MO, United States).
Sleep-Recording Surgeries
Animals (n = 25) were anesthetized with a mixture of
acepromazine (0.75 mg/Kg; i.p.), xylazine (2.5 mg/Kg; i.p.), and
ketamine (22 mg/Kg; i.p.) and placed in a stereotaxic frame
(David Kopf Instruments, Tujunga, CA, United States) for
standard sleep-recording electrodes implantation. Briefly, two
stainless-steel screw electrodes were inserted 2 mm on either side
of the sagittal sinus and 3 mm anterior to Bregma (frontal cortex)
whereas other two screws were located 3 mm on either side of
the sagittal sinus and 6 mm behind Bregma (occipital cortex).
This electrode setting recorded the electroencephalogram (EEG)
signal by obtaining the bipolar (differential) EEG signal recorded
from two contralateral screw electrodes (frontal–occipital). In
addition, the recording of the electromyogram (EMG) consisted
in the signal obtained by the implantation of two wire electrodes
into the dorsal neck muscles in each rat. Next, EEG/EMG
wires were inserted into a six-pin plastic plug (Plastics One,
Roanoke, VA, United States) and the whole electrode setting
was secured onto the skull by commercial dental cement.
Upon completion of the EEG/EMG surgeries, all animals were
placed into individual cages with regular bedding and standard
water and food containers for post-surgery recuperation period.
Rats with implanted electrodes were connected to a 6-channel
slip-ring commutator through a 50 cm cable (Plastics One,
Roanoke, VA, United States), which allowed to the animals to
free turning and moving around in the box during the whole
study. The surgical procedure as well as habituation conditions
(during 7 days) were carried out as reported elsewhere (Murillo-
Rodríguez et al., 2011b).
Sleep Recordings Analysis
The EEG/EMG signals were scored in 12 s epochs which
in turn allow to character the sleep-wake cycle in W, SWS,
or REMS by the sleep-scoring program (ICELUS). In detail:
The EEG/EMG wires were connected to the slip-ring system
(Plastics One, Roanoke, VA, United States) and to the amplifier
allowing to filter the EEG signal at 70 Hz (low-pass filter)
and 0.3 Hz (high-pass filter; Model M15LT 15A54; Grass
Instruments. Quincy, MA, United States). The EEG signals were
continuously sampled at 128 Hz by using a 100-bit analog-to-
digital converter board (NI PCI-6033E Multifunction I/O Board
and NI-DAQ Software, SCB-100 Shielded Connector Block.
National Instruments. Austin, TX, United States). With the aid
of the sleep-scoring software (ICELUS), the sleep-wake cycle was
characterized as follows: The presence of desynchronized EEG as
well as high EMG activity belong to the definition of W whereas
high-amplitude slow waves with a low EMG tone relative to
awake belong to SWS criteria. At last, REMS was characterized
by regular theta activity across the EEG coupled with low EMG
accompanied with myoclonic features. The sleep-recordings
procedures were followed as previously reported (Murillo-
Rodríguez et al., 2006, 2007b, 2008b,c; Mijangos-Moreno et al.,
2016).
Pharmacological Administrations
Right after 7 days of post-surgery and the respective habituation
period, animals were placed into one of the experimental light-
dark cycle block: Lights-on period (07:00–19:00 h) or lights-off
period (19:00–07:00 h). According to the respective experimental
light-dark block, animals were disconnected from the sleep-
recording system and experimental trials were administered
randomly as follows: VEH (n = 5), AA-5-HT (5, 10, 20 mg/Kg,
i.p.; n = 5 each group). Irrespective of whether the injection
of VEH could modify the sleep-wake cycle, an additional group
named “sham” (n= 5) was included in the light-dark period. This
group consisted in animals that received the insertion (i.p.) of
the needle but no administration was given. Once experimental
challenges were applied, animals were reattached to the sleep-
recording system and sleep data were collected across the
following 4h. In the current experiment, treatments were done
randomly by using a single-blind Latin Square Experimental
Design.
Power Spectra Analysis
Besides the effects of AA-5-HT on sleep, Fast Fourier
Transformation Analysis was collected during either lights-
on or lights-off cycle after respective treatments for analysis of
qualitative sleep parameters such as alpha, delta and theta power
spectra. Several reports have suggested that power spectra are a
critical element to circumscribe discrepancies among objective
and subjective measures of sleep-wake cycle (Tobler and Borbély,
1990; Franken et al., 1991; Corsi-Cabrera et al., 2001; Christensen
et al., 2015; Jing et al., 2016; Imperatori et al., 2016; Svetnik
et al., 2017). Thus, following standardized procedures, power
spectra for alpha (during W, α = 8–12 Hz), delta (across SWS,
1 = 0.5–4.0 Hz) or theta (for REMS, 2 = 6.0–12.0 Hz) were
analyzed after the experimental trials as previously reported
(Murillo-Rodríguez et al., 2011a).
Statistical Analysis
Data from sleep studies and power spectra experiments were
represented as mean ± standard error of the mean. Statistical
differences were determined by one-way ANOVA followed by
Scheffé’s post hoc test for multiple comparisons among the
experimental groups. All statistical analyses were performed
using the StatView (version 5.0.0, SAS Institute, United States)
and statistical differences among groups were determined if
P < 0.05.
Experiment 2: Effects on the
Extracellular Levels of Monoamines or
AD after Administrations of AA-5-HT
during the Lights-Off Period
Experimental Animals, Chemicals, and
Pharmacological Administrations
As described in Experiment 1.
Frontiers in Molecular Neuroscience | www.frontiersin.org 3 May 2017 | Volume 10 | Article 152
fnmol-10-00152 May 26, 2017 Time: 15:43 # 4
Murillo-Rodríguez et al. Injections of N-Arachidonoyl-Serotonin (AA-5-HT) Increase Sleep
Microdialysis Surgeries
Multiple experiments have suggested the key role of nucleus
accumbens (AcbC) in sleep modulation (Lazarus et al., 2012,
2013; Qiu et al., 2012; Zhang et al., 2013; Liu et al.,
2016). Furthermore, previous studies from our laboratory have
indicated reliable measurements of monoamines as well as
AD from AcbC (Murillo-Rodríguez et al., 2006; Mijangos-
Moreno et al., 2014, 2016). Thus, these evidences allowed
us to collect microdialysis samples from AcbC to determine
whether sleep changes provoked by AA-5-HT might be linked
with effects in neurotransmitters contents. To achieve this
goal, a new set of animals (n = 25) was anesthetized and
mounted into the stereotaxic frame (David Kopf Instruments.
Tujunga, CA, United States) for implantation of a microdialysis
guide-cannula (IC guide; BioAnalytical Systems [BAS], West
Lafayette, IN, United States). The cannula was unilaterally
placed into the AcbC (coordinates: A = +1.2 and L = +2.0,
H = –7.0 mm, with reference to Bregma [Paxinos and
Watson, 2005]) and right after the surgery, rats were placed
individually into the microdialysis bowl (Raturn Microdialysis
Stand-Alone System. MD-1404, BAS. West Lafayette, IN,
United States) for recovery as well as habituation for the
experimental conditions across 7 days. All surgical procedures of
microdialysis probes were accomplished as previously reported
(Murillo-Rodríguez et al., 2007a; Mijangos-Moreno et al., 2014,
2016).
Microdialysis Sampling Procedures
Seven days after microdialysis surgery, the rats were removed
from microdialysis bowls and the stylet from guide-cannula was
withdrawn. Later, the microdialysis probe (1 mm of length;
polyacrylonitrile, MWCO = 30,000 daltons; 340 µm OD; BAS.
West Lafayette, IN, United States) was inserted at 07:00 h.
Next, through a minitube (0.65 mm OD × 0.12 mm ID;
BAS, West Lafayette, IN, United States) attached to a 2.5 mL
syringe (BAS, West Lafayette, IN, United States) and using a
pump (flow rate: 0.25 µL/min; BAS Bee, West Lafayette, IN,
United States), artificial cerebrospinal fluid [aCSF (composition:
NaCl 147 mM, KCl 3 mM, CaCl 1.2 mM, MgCl 1.0 mM,
pH 7.2)] was injected. Importantly, previous experiments have
found that after insertion, the microdialysis probe requires
approximately 6–7 h for stabilization (Porkka-Heiskanen et al.,
2000; Murillo-Rodríguez et al., 2004). However, in the current
report, probes were stabilized during a total time of 24 h.
Later, and once stabilization period was achieved, microdialysis
samples were collected hourly across 4h from each animal
after experimental trials. Next, dialysates were averaged over
the four time points as a total value for each compound in
every experimental condition [Sham (n = 5), VEH (n = 5),
AA-5-HT (5, 10, or 20 mg/Kg, separately all doses (n = 5,
each dose))]. It is worthy to mention that the microdialysis
probes were used no more than 5 days since preceding reports
have shown that subsequently insertions, gliosis significantly
diminishes the membrane ability to transport fluid across
the pores (Porkka-Heiskanen et al., 2000; Murillo-Rodríguez
et al., 2004). Complementary, the recovery test of microdialysis
probes consisted in insertion of probes into a test solution
containing external known concentrations of monoamines or
AD with perfusion of aCSF at working flow rate (0.25 µL/min).
Microdialysates were collected under this experimental condition
after triplicate using a different lot of microdialysis probes. Each
sample collected from in vitro recovery study was analyzed and
the peak area ratio was calculated against the known standards
of neurotransmitters of interest. For obtaining the recovery
rate, data were calculated as follows: Recovery rate (%) = (the
peak area ratio of the sample from microdialysis sample)/(the
peak area ratio of the sample in the test solution). The whole
microdialysis procedures were carried out as previous reports
(Porkka-Heiskanen et al., 2000; Blanco-Centurion et al., 2006;
Mijangos-Moreno et al., 2014, 2016; Murillo-Rodríguez et al.,
2016).
Pharmacological Challenge
Seven days after microdialysis surgery and 24 h after stabilization
of microdialysis probes, experimental challenges were given
to animals as follows: Due to AA-5-HT induced sleep (see
Results section), animals were disconnected from microdialysis
system and treatments were randomly given during the lights-
off period. Right after the experimental trials were provided,
rats were reattached to the microdialysis system, placed them
back into the microdialysis bowls and sampling were collected
across 4 h. Later, all samples were stored (−80◦C) for further
analysis.
High-Performance Liquid Chromatography (HPLC)
Procedure
The collected dialysates were injected into HPLC for detection
and quantification of DA, NE, EP, 5-HT, and AD. In
detail: The dialysates were filtered (Millipore 0.22 µm; Merck
Millipore. Darmstadt, Germany) and injected into HPLC
(Modular Prominence, Shimadzu. Japan). The mobile phase for
monoamines consisted in monosodium phosphate [(7 mM, pH
3.0), plus methanol (3.5%)] perfused with a pump (LC-20AT,
Shimadzu, Japan) at flow rate of 80 µL/min. Separation of
molecules was achieved by using a microbore column [octadecyl
silica (3 µm, 100 × 1 mm), BAS, West Lafayette, IN, United
States] with temperature controlled (22◦C; oven CTO-20A.
Shimadzu, Japan). Samples were automatically injected (SIL-20A
HT Prominence HPLC, Shimadzu. Japan) into the HPLC and
chromatographic data were stored on a personal computer
(via computer controller CBM-20A, Shimadzu, Japan). To
determine the concentrations of DA, NE, EP, 5-HT, a series of
dilutions of known external standards of these neurotransmitters
were prepared and injected into HPLC. To ensure the specificity
of HPLC method, further procedures were carried out as
suggested by the manufacturer as well as reported by others
(Sartori et al., 2008; Mazzucchelli et al., 2011). Monoamines
were disclosed by using an electrochemical detector (LC-4C;
BAS, West Lafayette, IN, United States) as described by others
(Gold et al., 2011; Grupe et al., 2013). On the other hand, AD
detection required mobile phase prepared with 10 mM sodium
dihydrogen phosphate (pH 4.5) and methanol (9%), infused at
a flow rate of 80 µL/min using a pump (LC-20AT. Prominence
HPLC, Shimadzu, Japan). Detection of AD was carried out
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by using an UV detector (SPD-20A Prominence. Shimadzu,
Japan) set to a wavelength of 254 nm (deuterium lamp). All
chromatographic data for AD detection were recorded in a
personal computer, and peak heights of AD in dialysates were
compared with external standards using chromatograph report
software (LC Solution, Shimadzu, Japan). The procedure for
detection and measurement of monoamines or AD using HPLC
means was developed according to previous reports (Murillo-
Rodríguez et al., 2016).
Histological Verification of Probe Location
After microdialysis experiments, all rats were sacrificed with
a lethal dose of pentobarbital for the standard procedure for
the vascular perfusion. Animals were transcardially perfused
through a ventricular catheter placed on the left ventricle.
Next, the right atrium was cut open and saline solution
(0.9%) was perfused followed by formaldehyde (4%). The
brain was removed and post-fixed overnight in formaldehyde
(4%) followed by 10, 20, and 30% sucrose/PBS (0.1 M)
for 24 h each concentration. At last, all brains were cut
in coronal sections (20 µm) using a Portable Bench-top
Cryostat (Leica CM1100. Germany) and collected in 1:5 serial
order. One serial was used for probe location and it was
identified by plotting using rat brain atlas (Paxinos and Watson,
2005).
Statistical Analysis
As described in Experiment 1.
Experiment 3: AA-5-HT Blocks the
Wake-Inducing Properties of Cannabidiol
or Modafinil during the Lights-On Period
Experimental Animals, Chemicals, and
Pharmacological Administrations
As described in Experiment 1.
Pharmacological Administrations
To provide further evidence regarding the sleep-inducing
properties of AA-5-HT, we tested whether this compound would
block the waking induced by pharmacological means. In this
section of the study, administrations were given as described in
Experiment 1. However, we included in this section of the study,
the highest dose of AA-5-HT (20 mg/Kg; i.p.) as well as the wake-
inducing drug cannabidiol (CBD, 30 mg/Kg; i.p) or the stimulant
compound modafinil (MOD, 30 mg/Kg; i.p). To evaluate whether
AA-5-HT would prevent the alertness induced by either CBD
or MOD, the FAAH/TRPV1 modulator was administered (5, 10,
or 20 mg/Kg; n = 5, each group) 15 min before injection of
either MOD or CBD (30 mg/Kg; each separately; n = 5, each
group).
Power Spectra Analysis and Statistical Analysis
The analysis of power spectra after coadministrations of either
AA-5-HT + CBD or AA-5-HT + MOD and further statistical
analysis were carried out as described in Experiment 1.
Experiment 4: Effects on the
Extracellular Levels of Monoamines or
AD Induced by Cannabidiol or Modafinil
during the Lights-On Period Are
Prevented by AA-5-HT Injection
Experimental Animals, Chemicals, Microdialysis
Surgeries, Microdialysis Sampling Procedures, HPLC
Procedures, Histological Verification of Probe
Location, and Statistical Analysis
As described in Experiments 2 and 3. For studies when AA-5-HT
was administered before either injection of CBD or MOD,
statistical differences were determined by two-way ANOVA
followed by Scheffé’s post hoc test for multiple comparisons
among the experimental groups. All statistical analyses were
performed using the StatView (version 5.0.0, SAS Institute,
United States) and statistical differences among groups were
determined if P < 0.05.
Pharmacological Challenges
The analysis of extracellular levels of DA, NE, EP, 5-HT, and AD
after coadministrations of either AA-5-HT+MOD or AA-5-HT
+ CBD were carried out as described in Experiments 3 and 4.
Experiment 5: The Blockade of Sleep
Rebound Caused by Either Cannabidiol
or Modafinil after Total Sleep Deprivation
Is Prevented by AA-5-HT
Experimental Animals, Chemicals, and
Sleep-Recording Surgeries
As described in Experiments 1–4.
Total Sleep-Deprivation Procedure
Prolonged waking was carried out by maintaining rats on
constant continuous alertness across 6 h during the lights-on
period (from 07:00–13:00 h) by placing novel objects into
the cages, generating sounds, knocking the outer walls of the
cages, etc. (Mijangos-Moreno et al., 2015). During total sleep
deprivation (TSD, 6 h), sleep data were constantly recorded and
analyzed as reported (Murillo-Rodríguez et al., 2016).
Pharmacological Administrations
To test whether AA-5-HT would prevent the blocking effect
on sleep rebound after prolonged waking in CBD-treated or
MOD-injected rats, right after the end of TSD, rats were
disconnected from the sleep-recording system and experimental
trials were administered randomly as follows during the lights-on
period: Sham (n = 5), VEH (n = 5), AA-5-HT (5, 10, 20 mg/Kg,
i.p.; n = 5, each compound), CBD (30 mg/Kg, i.p.), MOD
(30 mg/Kg, i.p.), AA-5-HT (20 mg/Kg, i.p.) and 15 min later CBD
(30 mg/Kg, i.p.) or MOD (30 mg/Kg, i.p.). Once injections were
performed, rats were reattached to the sleep-recording system,
and sleep data were collected across the following 4h.
Power Spectra and Statistical Analysis
As described in Experiment 4.
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Experiment 6: The Blockade of the
Compensatory Rebound of the
Extracellular Levels of Monoamines or
AD after Total Sleep Deprivation by
Cannabidiol or Modafinil Is Prevented by
AA-5-HT during the Lights-On Period
Experimental Animals, Chemicals, Microdialysis
Surgeries, Microdialysis Sampling Procedures, HPLC
Procedures, Histological Verification of Probe
Location, Total Sleep-Deprivation, Pharmacological
Challenges Procedure and Statistical Analysis
As described in Experiments 1–5.
RESULTS
Experiment 1: Effects on Sleep after
Injections of AA-5-HT during Either the
Lights-On or Lights-Off Period
In the first experiment, AA-5-HT given during the lights-on
period, caused no significant differences in the sleep-wake cycle
between experimental groups (W: F(4,20) = 2.062, P = 0.1;
SWS: F(4,20) = 1.561, P = 0.2; REMS: F(4,20) = 1.614, P = 0.2;
Figures 1A–C, respectively). However, AA-5-HT administered
at the beginning of the lights-off period, decreased W
(F(4,20) = 7.991, P < 0.0005) and enhanced SWS (F(4,20) = 9.425,
P < 0.05) as well as REMS (F(4,20) = 8.324, P < 0.0004,
Figures 1D–F, respectively). The Scheffé’s post hoc test showed
statistical differences among sham/vehicle and AA-5-HT (5, 10,
20 mg/Kg) for waking, SWS and REMS during the lights-off
period (P < 0.01). From the data obtained, we conclude that
AA-5-HT caused sleep promotion if administered during the
lights-on period.
Regarding the power spectra analysis (alpha collected
during W, delta obtained during SWS and theta recorded
during REMS), we found that systemic injections during
the lights-on period of different doses of AA-5-HT (5, 10,
or 20 mg/Kg, i.p.) did not modify the values for alpha
(F(4,20) = 0.964, P = 0.4) or theta (F(4,20) = 1.524, P = 0.2)
whereas enhanced delta power spectra (F(4,20) = 3.053, P < 0.02;
Figures 2A–C, respectively). When AA-5-HT was administered
at the beginning of the lights-off period, a decrease in a
dose-dependent fashion in alpha was found (F(4,20) = 3.12,
P < 0.03) while an increase in delta (F(4,20) = 3.377,
P < 0.02) as well as a dose-dependent enhancement in theta
power spectra were observed (F(4,20) = 3.456, P < 0.02;
Figures 2D–F, respectively). The Scheffé’s post hoc test
displayed inter-group differences among sham/vehicle and
AA-5-HT (5, 10, 20 mg/Kg) for alpha, delta, and theta power
spectra (P < 0.02). Thus, we found that AA-5-HT caused a
dose-dependent effect in sleep power spectra by decreasing
alpha and enhancing theta power spectra. We conclude
that diminution observed in waking likely corresponds to
the decrease found in alpha power spectra. Conversely, the
enhancement in SWS and REMS caused by AA-5-HT is
accompanied by an increase in delta and theta power spectra,
respectively.
Experiment 2: Effects on the
Extracellular Levels of Monoamines or
AD after Administrations of AA-5-HT
during the Lights-Off Period
In the microdialysis experiments, position of probe was
confirmed as shown in Figure 3A. Since we observed that
AA-5-HT increased sleep during the active period of the
rats, in the microdialysis experiments, compound was given
at the beginning of the lights-off period. After injection
of AA-5-HT, we found a decrease in contents of DA
(F(4,20) = 7775.000, P < 0.0001), NE (F(4,20) = 1066.582,
P < 0.0001), EP (F (4,20) = 873.101; P < 0.0001) and 5-HT
(F(4,20) = 1288.113, P< 0.0001) whereas AA-5-HT enhanced AD
levels (F(4,20) = 773.200, P< 0.0001; Figures 3B–F, respectively).
A dose-dependent effect was observed in DA, NE, EP, 5-HT,
and AD contents in AA-5-HT-treated rats. The Scheffé’s post hoc
test showed inter-group differences between sham/vehicle and
AA-5-HT (5, 10, 20 mg/Kg) for DA, NE, EP, 5-HT, and AD
(P < 0.0001). We conclude that injection of AA-5-HT during
the lights-off period reduced in a dose-dependent fashion the
contents of monoamines whereas caused an opposite effect in AD
levels.
Experiment 3: AA-5-HT Blocks the
Wake-Inducing Properties of Cannabidiol
or Modafinil during the Lights-On Period
Next, we tested whether AA-5-HT would block the
wake-inducing effects of CBD during the lights-on period. Due
to ethical reasons, animals from sleep-wake study (sham, vehicle
and AA-5-HT groups, Figure 1) were used for comparisons in
this section of the experiment. As described previously, AA-5-HT
caused no statistical differences in waking, SWS and REMS if
injected during the lights-on period. However, administration
of CBD (30 mg/Kg, i.p.) enhanced alertness and decreased
SWS as well as REMS. This effects confirmed previous reports
(Murillo-Rodríguez et al., 2006, 2008b). Interestingly, AA-5-HT
administered 15min before the injection of CBD was able to
block the increase in W (F(4,20) = 14.502, P < 0.0001) as well
as the enhancement in SWS (F(4,20) = 8.372, P < 0.0004) and
REMS (F(4,20) = 3.675, P < 0.02; Figures 4A–C, respectively).
The Scheffé’s post hoc test showed inter-group differences for
among sham/vehicle and AA-5-HT as well as CBD and AA-5-HT
+ CBD for waking, SWS and REMS (P < 0.01). We conclude
that AA-5-HT blocked the wake-inducing effects of CBD.
Our next aim was to determine whether AA-5-HT might
prevent the alertness caused by MOD if injected at the beginning
of the lights-on period. Due to ethical reasons, rats from
sleep-wake study (sham, vehicle, and AA-5-HT groups, Figure 1)
were used for comparisons in this experiment. As described
previously, AA-5-HT caused no statistical differences in alertness,
SWS and REMS if injected at the beginning of the lights-on
period. Nevertheless, the administration of MOD (30 mg/Kg, i.p.)
increased W and decreased SWS. No statistical differences were
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FIGURE 1 | Effects on total time (4 h of sleep recordings) of wakefulness (W), slow wave sleep (SWS), and rapid eye movement sleep (REMS) after
experimental trials: Sham, vehicle or AA-5-HT (5, 10, or 20 mg/Kg; i.p.). No effects were observed in W, SWS, or REMS when AA-5-HT was injected during
the lights-on period (A–C, respectively). However, when administered at the beginning of the lights-off period, AA-5-HT decreased W and increased SWS and REMS
(D–F, respectively; Mean ± SEM ∗ vs. Sham/Vehicle, P < 0.05; & vs. AA-5-HT-5, P < 0.05; # vs. AA-5-HT-10, P < 0.05). Abbreviations: wakefulness (W), slow wave
sleep (SWS) and rapid eye movement sleep (REMS), AA-5-HT-5 mg/Kg (AA-5-HT-5), AA-5-HT-10 mg/Kg (AA-5-HT-10), AA-5-HT-20 mg/Kg (AA-5-HT-20).
found in REMS. The wake-inducing properties effects of MOD
in our experiment confirmed previous observations (Scammell
et al., 2000; Murillo-Rodríguez et al., 2007a, 2008c). Importantly,
administration of AA-5-HT 15 min before the injection of
MOD prevented the enhancement in waking (F(4,20) = 9.941,
P < 0.0001) as well as the diminution in SWS (F(4,20) = 9.409,
P < 0.0002; Figures 5A–C, respectively). The Scheffé’s post hoc
test showed inter-group differences for among sham/vehicle and
AA-5-HT as well as MOD and AA-5-HT + MOD for waking,
SWS and REMS (P < 0.0001). Our data suggest that AA-5-HT
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FIGURE 2 | Effects on EEG power spectra (alpha, delta or theta) after experimental trials: Sham, vehicle or AA-5-HT (5, 10, or 20 mg/Kg; i.p.). No
effects were observed in alpha or theta power spectra when AA-5-HT was injected during the lights-on period. (A–C) respectively). Next, when AA-5-HT was
administered at the beginning of the lights-off period, the compound decreased alpha (for W: α = 8–12 Hz), and enhanced delta (for SWS: 1 = 0.5–4.0 Hz) as well
as theta (for REMS: 2 = 6.0–12.0 Hz; (D–F). Mean ± SEM ∗ vs Sham/Vehicle, P < 0.05; & vs. AA-5-HT-5, P < 0.05; # vs. AA-5-HT-10, P < 0.05). Abbreviations:
slow wave sleep (SWS) and rapid eye movement sleep (REMS), AA-5-HT-5 mg/Kg (AA-5-HT-5), AA-5-HT-10 mg/Kg (AA-5HT-10), AA-5-HT-20 mg/Kg (AA-5-HT-20).
blocked the increase observed in waking as well as the decrease in
SWS caused by MOD.
In the following experiment, we evaluated if AA-5-HT would
block the effects of CBD in power spectra (alpha collected
during W, delta obtained during SWS and theta recorded during
REMS), during the lights-on period. Due to ethical reasons,
animals from power spectra experiment (sham, vehicle and
AA-5-HT groups, Figure 2) were used for comparisons in this
experiment. As showed previously, administration of AA-5-HT
caused no statistical changes in power spectra if injected during
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FIGURE 3 | Effects of administration of AA-5-HT (5, 10, or 20 mg/Kg; i.p.) during the lights-off period on the extracellular levels of dopamine (DA),
norepinephrine (NE), epinephrine (EP), serotonin (5-HT), and adenosine (AD). Schematic representation of position of the microdialysis probe into AcbC
(A- Black dots represent the tip of microdialysis probe). AA-5-HT decreased the contents of DA, NE, EP, and 5-HT whereas AD levels were enhanced (B–F,
respectively. Mean ± SEM ∗ vs. Sham/Vehicle, P < 0.05; & vs. AA-5-HT-5, P < 0.05; # vs. AA-5-HT-10, P < 0.05). Abbreviations: AA-5-HT-5 mg/Kg (AA-5-HT-5),
AA-5-HT-10 mg/Kg (AA-5-HT-10), AA-5-HT-20 mg/Kg (AA-5-HT-20). Drawing taken from Paxinos and Watson Rat Brain Atlas (2005).
the lights-on period. Notwithstanding, CBD (30 mg/Kg, i.p.)
increased alpha, and decreased delta as well as theta power
spectra. Moreover, administration of AA-5-HT before injection
of CBD prevented the enhancement caused by the cannabinoid
in alpha (F(4,20) = 5.463, P < 0.002), partially prevented the
diminution in delta (F(4,20) = 5.995, P < 0.002) and theta power
spectra (F(4,20) = 5.112, P < 0.002; Figures 6A–C, respectively).
Further analysis of intragroup effects (Schefféś post hoc test)
showed differences among sham/vehicle and AA-5-HT as well
as CBD and AA-5-HT + CBD for alpha, delta and theta power
spectra (P < 0.001). We conclude that AA-5-HT was able to
block the increase in alpha power spectra whereas a limited
preventing effect was observed in delta and theta power spectra
in CBD-treated rats.
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FIGURE 4 | Effects on total time of W, SWS, and REMS after
experimental trials administered at the beginning of the lights-on
period: Sham, vehicle, AA-5-HT (20 mg/Kg; i.p.), cannabidiol (CBD,
30 mg/Kg; i.p.) or AA-5-HT (20 mg/Kg; i.p.) and 15 min CBD (30 mg/Kg;
i.p.). AA-5-HT caused no statistical difference in waking, SWS and REMS.
However, CBD (30 mg/Kg; i.p.) enhanced alertness and decreased SWS as
well as REMS. Interestingly, AA-5-HT administered 15min before the injection
of CBD blocked the increase in W as well as the enhancement in SWS and
partially REMS caused by CBD (A–C, respectively; Mean ± SEM ∗ vs.
Sham/Vehicle, P < 0.05; & vs. AA-5-HT-20, P < 0.05; # vs. CBD-30,
P < 0.05). Abbreviations: Cannabidiol 30 mg/Kg, i.p. (CBD-30),
AA-5-HT-20 mg/Kg (AA-5-HT-20).
FIGURE 5 | Effects on total time of W, SWS, and REMS after
experimental trials: Sham, vehicle, AA-5-HT (20 mg/Kg; i.p.), modafinil
(MOD, 30 mg/Kg; i.p.) or AA-5-HT (20 mg/Kg; i.p.) and 15 min MOD
(30 mg/Kg; i.p.). AA-5-HT caused no statistical difference in waking, SWS
and REMS if injected at the beginning of the lights-on period. However, the
administration of MOD (30 mg/Kg; i.p.) increased W and decreased SWS. No
statistical changes were observed in REMS in MOD-treated animals.
Interestingly, administration of AA-5-HT 15 min before the injection of MOD
prevented the enhancement in waking as well as the diminution in SWS.
Despite that MOD induced no effects in REMS, combination of AA-5-HT +
MOD decreased REMS (A–C, respectively) induced by the stimulant
(Mean ± SEM ∗ vs. Sham/Vehicle, P < 0.05; & vs. AA-5-HT-20, P < 0.05;
# vs. MOD-30, P < 0.05). Abbreviations: Modafinil 30 mg/Kg, i.p. (MOD-30),
AA-5-HT-20 mg/Kg (AA-5-HT-20).
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FIGURE 6 | Effects on EEG power spectra (alpha [for W: α = 8–12 Hz],
delta [for SWS: 1 = 0.5–4.0 Hz] or theta [for REMS: 2 = 6.0–12.0 Hz])
after experimental trials: Sham, vehicle, AA-5-HT (20 mg/Kg; i.p.),
cannabidiol (CBD; 30 mg/Kg; i.p.) or AA-5-HT (20 mg/Kg; i.p.) and
15 min CBD (30 mg/Kg; i.p.) at the beginning of the lights-on period.
Administration of AA-5-HT caused no statistical changes in power spectra.
However, CBD (30 mg/Kg; i.p.) increased alpha, and decreased delta as well
as theta power. Moreover, administration of AA-5HT before injection of CBD
prevented the changes caused by the cannabinoid in alpha and partially delta
and theta power spectra spectra (A–C, respectively; Mean ± SEM ∗ vs.
Sham/Vehicle, P < 0.05; & vs. AA-5-HT-20, P < 0.05; # vs. CBD-30,
P < 0.05). Abbreviations: Cannabidiol 30 mg/Kg, i.p. (CBD-30),
AA-5-HT-20 mg/Kg (AA-5-HT-20).
FIGURE 7 | Effects on EEG power spectra (alpha [for W: α = 8–12 Hz],
delta [for SWS: 1 = 0.5-4.0 Hz], or theta [for REMS: 2 = 6.0–12.0 Hz])
after experimental trials: Sham, vehicle, AA-5-HT (20 mg/Kg; i.p.),
modafinil (MOD; 30 mg/Kg; i.p.) or AA-5-HT (20 mg/Kg; i.p.) and 15 min
MOD (30 mg/Kg; i.p.) at the beginning of the lights-on period. AA-5-HT
caused no statistical effects in power spectra. However, injection of MOD
(30 mg/Kg; i.p.) increased alpha and decrease delta and theta power spectra.
Moreover, injection of AA-5-HT before administration of MOD was able to
block the enhancement in in alpha, delta and theta power spectra (A–C,
respectively. Mean ± SEM ∗ vs. Sham/Vehicle, P < 0.05; & vs. AA-5-HT-20,
P < 0.05; # vs. MOD-30, P < 0.05). Abbreviations: Modafinil 30 mg/Kg, i.p.
(MOD-30), AA-5-HT-20 mg/Kg (AA-5-HT-20).
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Whether AA-5-HT would be able to block the effects of MOD
in power spectra during the lights-on period was evaluated in
the next experiment. By reasons of ethical issues, rats from
power spectra experiment (sham, vehicle and AA-5-HT groups,
Figure 2) were used for comparisons in this section of the
study. We found that AA-5-HT caused no statistical effects
in power spectra. However, injection of MOD (30 mg/Kg,
i.p.) during the lights-on period increased alpha and decrease
delta and theta power spectra. Moreover, administration of
AA-5-HT before injection of MOD blocked the enhancement
in alpha (F(4,20) = 6.872, P < 0.01), and prevented the
decrease in delta (F(4,20) = 4.715, P < 0.01) and theta
power spectra (F(4,20) = 5.501, P < 0.01; Figures 7A–C,
respectively). Statistical intragroup analysis (Scheffé’s post hoc
test) showed differences among sham/vehicle and AA-5-HT as
well as MOD and AA-5-HT + MOD for alpha, delta, and
theta power spectra (P < 0.01). In conclusion, we observed that
AA-5-HT prevented the enhancement in alpha as well as the
diminution in delta and theta power spectra caused by MOD
injection.
Experiment 4: Effects on the
Extracellular Levels of Monoamines or
AD Induced by Cannabidiol or Modafinil
during the Lights-On Period Are
Prevented by AA-5-HT Injection
In the next set of experiments, we described the blocking
effects of AA-5-HT on the extracellular levels of DA, NE,
EP, 5-HT, and AD in response to CBD during the lights-on
period. Administration of AA-5-HT decreased extracellular
contents of DA, NE, 5-HT, and increased AD levels as
well. No statistical differences were found in EP contents.
Moreover, injection of CBD (30 mg/Kg, i.p.) increased all
neurotransmitters studied. Next, the administration of AA-5-HT
before injection of CBD partially prevented the enhancement
in DA as shown by two-way ANOVA (F(4,20) = 1964.342,
P < 0.0001), and blocked the increase in NE (F(4,20) = 451.868,
P < 0.0001), EP (F(4,20) = 107.976, P < 0.0001), 5-HT
(F(4,20) = 790.761, P < 0.0001) as well as the enhancement
in AD levels (F(4,20) = 843.897, P < 0.0001; Figures 8A–E,
respectively). Further Scheffé’s post hoc test showed inter-group
differences among sham/vehicle and AA-5-HT as well as CBD
and AA-5-HT+ CBD in levels of DA, NE, EP, 5-HT, AD
(P < 0.0001). We conclude that injection of AA-5-HT before
administration of CBD was able to block the enhancement
in the levels of neurotransmitters in response to CBD
administration.
To further characterize whether AA-5-HT administered
before MOD would prevent the effects of this stimulant on the
extracellular levels of DA, NE, EP, 5-HT, and AD during the
lights-on period, we developed the corresponding experiment.
Considering ethical reasons, animals from microdialysis study
(sham, vehicle and AA-5-HT groups, Figure 8) were used for
comparisons in this experiment. It was found that AA-5-HT
decreased the extracellular contents of DA, NE, 5-HT whereas
increased levels of AD. No statistical differences were found in
EP extracellular contents. On the other hand, MOD induced
opposite effects since enhanced extracellular levels of DA,
NE, EP, 5-HT while decreased contents of AD. Importantly,
administration of AA-5-HT before the injection of MOD
partially prevented the increase in levels of DA as analyzed
by two-way ANOVA (F(4,20) = 1798.342, P < 0.0001), NE
(F(4,20) = 237.909, P < 0.0001), EP (F(4,20) = 208.533,
P < 0.0001), 5-HT (F(4,20) = 1198.470, P < 0.0001) and
blocked the decrease in levels of AD (F(4,20) = 1614.168,
P < 0.0001; Figures 9A–E, respectively). Further Scheffé’s post
hoc test showed inter-group differences between sham/vehicle
and AA-5-HT as well as MOD and AA-5-HT + MOD for DA,
NE, EP, 5-HT, and AD (P < 0.0001). Based in our findings,
it can be concluded that AA-5-HT prevented the effects in
neurotransmitters caused by CBD injection during the lights-on
period.
Experiment 5: The Blockade of Sleep
Rebound Caused by Either Cannabidiol
or Modafinil after Total Sleep Deprivation
Is Prevented by AA-5-HT
As shown previously in the current report, AA-5-HT
promoted sleep during the active period of rats and decreased
wake-related neurotransmitters. Moreover, this drug blocked
the wake-promoting effects of CBD or MOD. However, to
characterize the properties of AA-5-HT in sleep homeostasis,
we explored the possibility that the blockade by CBD or
MOD of the compensatory sleep rebound after TSD would
be prevented by injection of AA-5-HT during the lights-on
period. We found that AA-5-HT caused no statistical changes
in W, SWS or REMS if given after TSD. Moreover, during
the sleep rebound period, CBD or MOD increased waking
and decreased SWS and REMS. Interestingly, during the sleep
rebound period, the administration of AA-5-HT before injection
of CBD partially prevented the increase in W as shown by
two-way ANOVA (F(6,28) = 6063.477; P < 0.0001) as well as the
decrease in SWS (F(6,28) = 3649.311; P < 0.0001) and REMS
(F(6,28) = 1050.707; P < 0.0001; Figures 10A–C, respectively).
Similar results were obtained when AA-5-HT was administered
before MOD during sleep rebound period. Further Scheffé’s post
hoc test showed inter-group differences among sham/vehicle
and AA-5-HT as well as CBD, MOD, AA-5-HT + CB as well as
AA-5-HT + MOD for alertness, SWS and REMS (P < 0.0001).
We conclude that AA-5-HT was partially able to prevent the
enhancement in W as well as the decrease in SWS or REMS
caused by either CDB or MOD during sleep rebound period after
TSD.
Next, we evaluated the changes of power spectra after
TSD in animals that received AA-5-HT, CBD, MOD or
administration of AA-5-HT before either CBD or MOD. We
found that AA-5-HT caused no effects in power spectra.
However, CBD or MOD increased alpha and decreased delta and
theta power spectra. The most prominent effect was observed
in CBD-treated animals. Importantly, the administration of
AA-5-HT before injection of either CBD or MOD partially
diminished the increase in alpha as tested by two-way
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FIGURE 8 | Effects on the extracellular levels of DA, NE, EP, 5-HT, and AD after the administration of AA-5-HT (20 mg/Kg; i.p.), cannabidiol (CBD;
30 mg/Kg; i.p.) or AA-5-HT (20 mg/Kg; i.p.) and 15 min CBD (30 mg/Kg; i.p.) at the beginning of the lights-on period. Administration of AA-5-HT
decreased extracellular contents of DA, NE, 5-HT and increased AD levels as well. No statistical differences were observed in NE contents. Moreover, injection of
CBD (30 mg/Kg; i.p.) increased all neurotransmitters levels. Next, the administration of AA-5-HT before injection of CBD was able to prevent the enhancement in DA,
NE, EP, 5-HT as well as AD levels (A–E, respectively. Mean ± SE. ∗ vs. Sham/Vehicle, P < 0.05; & vs. AA-5-HT-20, P < 0.05; # vs. CBD-30, P < 0.05).
Abbreviations: Cannabidiol 30 mg/Kg, i.p. (CBD-30), AA-5-HT-20 mg/Kg (AA-5-HT-20).
ANOVA (F(6,28) = 4.474, P < 0.004), blocked the diminution
in delta (F(6,28) = 4.079, P < 0.004) and prevented the
decrease in theta power spectra (F(6,28) = 5.109, P < 0.004;
Figures 11A–C, respectively) during sleep rebound period.
Additionally, inter-group differences were found by Scheffé’s post
hoc test for alpha, delta, and theta power spectra (P < 0.0001).
We conclude that AA-5-HT was partially able to prevent the
effects on power spectra after either CBD or MOD injection
after TSD.
Experiment 6: The Blockade of the
Compensatory Rebound of the
Extracellular Levels of Monoamines or
AD after Total Sleep Deprivation by
Cannabidiol or Modafinil Is Prevented by
AA-5-HT during the Lights-On Period
In the last experiment, we investigated whether the blockade
of the compensatory balance of the extracellular levels of DA,
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FIGURE 9 | Effects on the extracellular levels of DA, NE, EP, 5-HT, and AD after the administration of AA-5-HT (20 mg/Kg; i.p.), modafinil (MOD;
30 mg/Kg; i.p.) or AA-5-HT (20 mg/Kg; i.p.), and 15 min MOD (30 mg/Kg; i.p.) at the beginning of the lights-on period. AA-5-HT decreased the
extracellular contents of catecholamines whereas increased levels of AD. On the other hand, MOD induced opposite effects. Importantly, administration of AA-5-HT
before the injection of MOD partially was able to prevent the increase in levels of DA, NE, EP, 5-HT, and blocked the decrease of AD contents (A–E, respectively.
Mean ± SEM ∗ vs. Sham/Vehicle, P < 0.05; & vs. AA-5-HT-20, P < 0.05; # vs. MOD-30, P < 0.05). Abbreviations: Modafinil 30 mg/Kg, i.p. (MOD-30),
AA-5-HT-20 mg/Kg (AA-5-HT-20).
NE, EP, 5-HT, or AD after TSD by either CBD or MOD
would be prevented by AA-5-HT. We found that AA-5-HT
decreased after TSD the extracellular levels of neurotransmitters
studied. Moreover, injection of either CBD or MOD increased
the contents of DA as determined by two-way ANOVA
(F(6,28) = 1952.414, P < 0.0001), NE (F(6,28) = 436.222,
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FIGURE 10 | Effects of experimental trials: Sham, vehicle, AA-5-HT
(20 mg/Kg; i.p.), cannabidiol (CBD; 30 mg/Kg; i.p.), AA-5-HT (20 mg/Kg;
i.p.) and 15 min later CBD (30 mg/Kg; i.p.), modafinil (MOD; 30 mg/Kg;
i.p.) or AA-5-HT (20 mg/Kg; i.p.) and 15 min later MOD (30mg/Kg; i.p.)
on W, SWS, or REMS during the sleep rebound period in
sleep-deprived rats. AA-5-HT caused no statistical changes in W, SWS or
REMS after total sleep deprivation. Moreover, during the sleep rebound
period, CBD or MOD increased waking and decreased SWS and REMS.
Interestingly, during the sleep rebound period, the administration of AA-5-HT
before injection of CBD prevented the increase in W as well as the decrease in
SWS and partially REMS in CBD-treated rats. Similar results in sleep were
obtained when AA-5-HT was administered before MOD after total sleep
deprivation (A–C, respectively. Mean ± SEM ∗ vs. Sham/Vehicle, P < 0.05; &
vs. AA-5HT-20, P < 0.05; # vs. CBD-30, P < 0.05; % vs. MOD-30, P < 0.05).
Abbreviations: Cannabidiol 30 mg/Kg, i.p. (CBD-30), modafinil 30 mg/Kg, i.p.
(MOD-30), AA-5-HT-20 mg/Kg (AA-5-HT-20).
FIGURE 11 | Effects of experimental trials: Sham, vehicle, AA-5-HT
(20 mg/Kg; i.p.), cannabidiol (CBD; 30 mg/Kg; i.p.), AA-5-HT (20 mg/Kg;
i.p.) and 15 min later CBD (30 mg/Kg; i.p.), modafinil (MOD; 30 mg/Kg;
i.p.) or AA-5-HT (20 mg/Kg; i.p.) and 15 min later MOD (30 mg/Kg; i.p.)
during the sleep rebound period in sleep-deprived rats on power
spectra alpha (for W: α = 8–12 Hz), delta (for SWS: 1 = 0.5–4.0 Hz) or
theta power spectra (for REMS: 2 = 6.0–12.0 Hz). AA-5-HT caused no
effects in power spectra. However, CBD or MOD partially increased alpha and
decreased delta and theta power spectra. Importantly, the administration of
AA-5-HT before injection of either CBD of MOD prevented the increase in
alpha as well as blocked the diminution in delta and theta (A–C, respectively.
Mean ± SEM ∗ vs. Sham/Vehicle, P < 0.05; & vs. AA-5-HT-20, P < 0.05; #
vs. CBD-30, P < 0.05; % vs. MOD-30, P < 0.05). Abbreviations: Cannabidiol
30 mg/Kg, i.p. (CBD-30), modafinil 30 mg/Kg, i.p. (MOD-30),
AA-5-HT-20 mg/Kg (AA-5-HT-20).
Frontiers in Molecular Neuroscience | www.frontiersin.org 15 May 2017 | Volume 10 | Article 152
fnmol-10-00152 May 26, 2017 Time: 15:43 # 16
Murillo-Rodríguez et al. Injections of N-Arachidonoyl-Serotonin (AA-5-HT) Increase Sleep
P < 0.0001), EP (F(6,28) = 212.732, P < 0.0001), 5-HT
(F(6,28) = 1384.522; P < 0.0001) and AD (F(6,28) = 1743.304,
P < 0.0001; Figures 12A–E, respectively) during the sleep
rebound period. The most prominent effect was observed in
CBD-injected rats. Moreover, inter-group differences were found
by Scheffé’s post hoc between sham/vehicle and AA-5-HT, CBD,
MOD, AA-5-HT + CB as well as AA-5-HT + MOD for DA,
NE, EP, 5-HT, and AD (P < 0.0001). Combination of AA-5-HT
+ CBD partially blocked the enhancement in neurotransmitters
levels in CBD-treated animals. Similar findings were observed
in MOD-treated rats. We conclude that AA-5-HT did not fully
block the enhancement found in neurotransmitters in animals
that received either CBD or MOD during sleep rebound period
after TSD.
DISCUSSION
The endocannabinoid system exerts multiple and complex
modulatory physiological functions (Kendall and Yudowski,
2016; Ligresti et al., 2016; Argueta and DiPatrizio, 2017; Bennett
et al., 2017; Dos Anjos-Garcia et al., 2017; Sun et al., 2017). For
instance, cumulative evidence has suggested that the elements of
the endocannabinoid system, including FAAH, control the sleep-
wake cycle (Santucci et al., 1996; Murillo-Rodríguez et al., 1998,
2001, 2003, 2008a, 2011a, 2013, 2016; Herrera-Solis et al., 2010;
Rueda-Orozco et al., 2010; Pava et al., 2014, 2016). In this regard,
an experimental approach to explore the role of FAAH in sleep
modulation has consisted in the characterization of the properties
of FAAH inhibitors, such as URB597 (Murillo-Rodríguez
et al., 2007b, 2011a, 2016). Among FAAH inhibitors, several
compounds such as 1-heteroarylpropan-2-ones, piperidinyl
thiazole isoxazoline, PF-04457845, JNJ-42165279, BIA 10-2474,
AM3506, URB694, ARN146333-carboxamido-5-aryl-isoxazole,
N-aryl 2-aryloxyacetamides have been reported with significant
activity. It is worthy to mention that URB597 has been
described as one of the most potent FAAH inhibitors so
far (Carnevali et al., 2015; Keith et al., 2015; Lodola et al.,
2015; Doenni et al., 2016; Panlilio et al., 2016; Pember et al.,
2016; Tong et al., 2016; Tuo et al., 2016; Zahov et al., 2017;
Sunduru et al., 2017; Wilkerson et al., 2017). However, full
description of these FAAH inhibitors in sleep control requires
attention.
AA-5-HT is a dual blocker of FAAH/TRPV1 that shows
multiple pharmacological effects. For instance, this compound
produces anxiolytic-like effects in mice tested in the open arms
(Micale et al., 2009; John and Currie, 2012). Moreover, AA-
5-HT also reduces depression-like behaviors without changing
locomotor activity (Navarria et al., 2014; Sartim et al., 2017).
It is worthy to note that to our knowledge, the current
report provides for the very first time direct evidence about
the effects of AA-5-HT in sleep modulation. In this regard,
the systemic injection of this drug increased sleep during
the lights-off, but not in the lights-on period. Moreover, we
found that AA-5-HT enhanced power spectra linked to sleep
such as delta and theta whereas neurotransmitters associated
to waking were found decreased during the lights-off period.
Furthermore, in our experiments, AA-5-HT prevented the
blockade of the effects of CBD or MOD on sleep rebound as
well as neurotransmitters changes after TSD. Taking together,
these data suggest that either FAAH or TRPV1 or both might
be modulating sleep, sleep homeostasis and neurotransmitter
contents in the presence of wake-promoting compounds such
as CBD or MOD. Although a mechanistic approach was
not addressed in the current report, we would like to draw
the following hypothetical scenario (Figure 13): AA-5-HT
inhibits FAAH leading to the enhancement in contents of
oleoylethanolamide (OEA), palmitoylethanolamide (PEA) as well
as AEA (de Lago et al., 2005; Palazzo et al., 2010). Whereas
OEA binds to PPARα in the nucleus and promotes waking
(Mijangos-Moreno et al., 2016), AEA is able to diffuse across
the cellular membrane by AMT to bind either CB1 cannabinoid
receptors or TRPV1 (Leung et al., 2013; Nicolussi and Gertsch,
2015). While activation of CB1 cannabinoid receptor has been
linked with sleep generation (Murillo-Rodríguez et al., 2001,
2003, 2016), further evidence is required to fully determine
whether activation of TRPV1 modulates sleep. As mentioned
previously, FAAH inhibition may also lead to the increase
in the levels of other FAAH substrates. Indeed, Wollank
et al. (2015) demonstrated higher levels of AEA, 2-AG, OEA,
and PEA in cells incubated with AA-5-HT. These data were
confirmed by LC-MS analyses in in vitro studies showing
an enhancement of the levels of AEA-like lipids, including
OEA and PEA with URB597 (Winkler et al., 2016). If FAAH
inhibition promotes waking (Murillo-Rodríguez et al., 2007b,
2011a), how can we reconcile the current results with available
evidence in the literature? Since AEA modulates multiple
neurobiological functions also acting via TRPV1 (Di Marzo
and De Petrocellis, 2012; Starowicz et al., 2012), then a
hypothetical explanation would be that AA-5-HT increases sleep
via the involvement of TRPV1 activated by AEA. However,
the TRPV1 agonist capsaicin increases the firing rate of rat
DA neurons (Marinelli et al., 2005; Chakraborty et al., 2016).
Moreover, AA-5-HT promotes the electrophysiological activity
of locus coeruleus neurons (de Novellis et al., 2008). It is
widely accepted that both brain areas are related with waking
since their firing rates are higher across alertness rather than
during sleep (Berridge et al., 2012). Thus, discrepancies between
current results and available evidence might involve –besides
methodological differences between comparable studies- a more
complex mechanism of action. It can be proposed that AA-
5-HT induces sleep not only by facilitating endogenous AEA
action at CB1 cannabinoid receptors but also by antagonizing
its activation of TRPV1. Thus our data lead us to speculate
that AA-5-HT acts as a dual FAAH inhibitor and TRPV1
antagonist, but this should not necessarily be viewed as
predictable, because: (1) the activity of AA-5-HT is exerted
at higher concentrations comparted to other more potent
FAAH inhibitors, such as URB597, and (2) the role of AEA
as a full or partial agonist of TRPV1 to promote sleep lacks
full investigation. Nevertheless, AA-5-HT could show higher
preference for binding to TRPV1 resulting in an increase in
AEA levels which in turn will lead to sleep promotion via
activation of CB1 cannabinoid receptors and not to sleep
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FIGURE 12 | Effects of experimental trials: Sham, vehicle, AA-5-HT (20 mg/Kg; i.p.), cannabidiol (CBD; 30 mg/Kg; i.p.), AA-5-HT (20 mg/Kg; i.p.) and
15 min later CBD (30 mg/Kg; i.p.), modafinil (MOD; 30 mg/Kg; i.p.) or AA-5-HT (20 mg/Kg; i.p.) and 15 min later MOD (30 mg/Kg; i.p.) during the sleep
rebound period in sleep-deprived rats on extracellular levels of DA, NE, EP, 5-HT, and AD. AA-5-HT decreased extracellular levels of all neurotransmitters
studied. Moreover, injection of either CBD or MOD increased the contents of DA, NE, EP, 5-HT and AD (A–E, respectively) during the sleep rebound period.
Importantly, combination of AA-5-HT + CBD partially prevented the CBD-induced changes in neurotransmitters. Similar results were observed in AA-5-HT +
MOD-treated rats compared to MOD-injected animals (Mean ± SEM ∗ vs. Sham/Vehicle, P < 0.05; & vs. AA-5-HT-20, P < 0.05; # vs. CBD-30, P < 0.05; % vs.
MOD-30, P < 0.05). Abbreviations: Cannabidiol 30 mg/Kg, i.p. (CBD-30), modafinil 30 mg/Kg, i.p. (MOD-30), AA-5-HT-20 mg/Kg (AA-5-HT-20).
inhibition via TRPV1. Studies addressing the displacement of
AA-5-HT from binding sites of TRPV1 simultaneously with AEA
will provide new insights regarding endocannabinoid system
function.
Lastly, although there are no comparative studies between
the different experimental approaches on what could be
the most reliable strategy for the manipulation of the
endocannabinoid system (endogenous ligands, receptors,
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FIGURE 13 | Hypothetical molecular mechanism of action of AA-5-HT in sleep promotion. In this empirical proposal, AA-5-HT inhibits fatty acid amide
hydrolase (FAAH) which in turn increases levels of oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) as well as anandamide (AEA). Whereas OEA binds to
PPARα in nucleus and promotes waking, AEA is able to diffuse across the cellular membrane by anandamide membrane transporter (AMT) to bind either CB1
cannabinoid receptor or TRPV1. AA-5-HT can also antagonize AEA action at TRPV1. While activation of CB1 cannabinoid receptor has been linked with sleep
generation, further evidence is needed to determine whether activation or inhibition of TRPV1 would modulate sleep.
transporters, synthesizing/degrading enzymes, etc.) in sleep
modulation, the current report provides further evidence
for the role of AA-5-HT in sleep control. At this date,
the neuromolecular role of the endocannabinoid system in
sleep-wake cycle regulation has provided important insights
regarding the involvement of AEA, CB1 cannabinoid receptor,
AMT, as well as FAAH (Murillo-Rodríguez et al., 1998,
2001, 2003, 2007b, 2008a, 2011a, 2016; Herrera-Solis et al.,
2010; Pava et al., 2014, 2016; Rueda-Orozco et al., 2010).
However, the identification of new compounds targeting
the endocananbinoid system will help validating the role of
this system in sleep control highlighting the most pertinent
drug with highest efficiency and lowest side effects in animal
models (Lauria et al., 2015; Nimczick and Decker, 2015; Bertini
et al., 2016; Aizpurua-Olaizola et al., 2017; Chicca et al.,
2017).
Indeed, studies are needed to fully describe the
mechanism of action by which AA-5-HT promotes sleep
and modulates power spectra activity. Moreover, the
regulation of enzymes responsible for neurotransmitter
synthesis and/or degradation under the influence of AA-
5-HT is also unknown. In addition, the role of AA-5-HT
as a blocker of alertness caused by CBD or MOD during
the sleep rebound period after TSD still requires further
studies.
CONCLUSION
In summary, AA-5-HT promotes sleep and decreases waking-
related neurotransmitters in the lights-off period, and modulates
sleep homeostasis in the presence of wake-promoting
compounds such as CBD or MOD. The full understanding
of the mechanisms through which AA-5-HT modulates sleep
awaits further investigation.
AUTHOR CONTRIBUTIONS
EM-R designed, performed the experiments, analyzed data and
wrote the Manuscript. VD provided methodological support and
contributed to writing the manuscript. SM revised experimental
design. NBR, ABV, GAMN, HB, OA-C, revised analyzed data.
GA-S provided methodological support. All authors revised the
whole paper and approved the final version of the manuscript.
ACKNOWLEDGMENT
This work was supported by funding (given to EM-R; Grant
Number 03-1213) from Escuela de Medicina, Universidad
Anáhuac Mayab, Merida, Yucatán, México.
Frontiers in Molecular Neuroscience | www.frontiersin.org 18 May 2017 | Volume 10 | Article 152
fnmol-10-00152 May 26, 2017 Time: 15:43 # 19
Murillo-Rodríguez et al. Injections of N-Arachidonoyl-Serotonin (AA-5-HT) Increase Sleep
REFERENCES
Aizpurua-Olaizola, O., Elezgarai, I., Rico-Barrio, I., Zarandona, I., Etxebarria, N.,
and Usobiaga, A. (2017). Targeting the endocannabinoid system: future
therapeutic strategies. Drug Discov. Today 1, 105–110. doi: 10.1016/j.drudis.
2016.08.005
Argueta, D. A., and DiPatrizio, N. V. (2017). Peripheral endocannabinoid signaling
controls hyperphagia in western diet-induced obesity. Physiol. Behav. 171,
32–39. doi: 10.1016/j.physbeh.2016.12.044
Barateau, L., Lopez, R., and Dauvilliers, Y. (2016). Management of narcolepsy.
Curr. Treat. Options Neurol. 18, 43. doi: 10.1007/s11940-016-0429-y
Bennett, M. R., Arnold, J., Hatton, S. N., and Lagopoulos, J. (2017). Regulation
of fear extinction by long-term depression: the roles of endocannabinoids and
brain derived neurotrophic factor. Behav. Brain Res. 319, 148–164. doi: 10.1016/
j.bbr.2016.11.029
Berridge, C. W., Schmeichel, B. E., and Espana, R. A. (2012). Noradrenergic
modulation of wakefulness/arousal. Sleep Med. Rev. 16, 187–197. doi: 10.1016/
j.smrv.2011.12.003
Bertini, S., Chicca, A., Arena, C., Chicca, S., Saccomanni, G., Gertsch, J., et al.
(2016). Synthesis and pharmacological evaluation of new biphenylic derivatives
as CB2 receptor ligands. Eur. J. Med. Chem. 116, 252–266. doi: 10.1016/j.ejmech.
2016.03.072
Biernacki, M., and Skrzydlewska, E. (2016). Metabolism of endocannabinoids.
Postepy Hig. Med. Dosw. 70, 830–843. doi: 10.5604/17322693.1213898
Blanco-Centurion, C., Xu, M., Murillo-Rodríguez, E., Gerashchenko, D.,
Shiromani, A. M., Salin-Pascual, R. J., et al. (2006). Adenosine and sleep
homeostasis in the Basal forebrain. J. Neurosci. 26, 8092–8100. doi: 10.1523/
JNEUROSCI.2181-06.2006
Carnevali, L., Vacondio, F., Rossi, S., Macchi, E., Spadoni, G., Bedini, A., et al.
(2015). Cardioprotective effects of fatty acid amide hydrolase inhibitor URB694,
in a rodent model of trait anxiety. Sci. Rep. 5:18218. doi: 10.1038/srep18218
Chakraborty, S., Rebecchi, M., Kaczocha, M., and Puopolo, M. (2016). Dopamine
modulation of transient receptor potential vanilloid type 1 (TRPV1) receptor in
dorsal root ganglia neurons. J. Physiol. 594, 1627–1642. doi: 10.1113/JP271198
Chen, D. J., Gao, M., Gao, F. F., Su, Q. X., and Wu, J. (2017). Brain cannabinoid
receptor 2: expression, function and modulation. Acta Pharmacol. Sin. 38,
312–316. doi: 10.1038/aps.2016.149
Chen, J., Varga, A., Selvarajah, S., Jenes, A., Dienes, B., Sousa-Valente, J.,
et al. (2016). Spatial Distribution of the cannabinoid type 1 and capsaicin
receptors may contribute to the complexity of their crosstalk. Sci. Rep. 6:33307.
doi: 10.1038/srep33307
Chicca, A., Berg, R., Jessen, H. J., Marck, N., Schmid, F., Burch, P., et al. (2017).
Biological evaluation of pyridone alkaloids on the endocannabinoid system.
Bioorg. Med. Chem. 16, 31251–31252. doi: 10.1016/j.bmc.2017.02.031
Christensen, J. A., Munk, E. G., Peppard, P. E., Young, T., Mignot, E., Sorensen,
H. B., et al. (2015). The diagnostic value of power spectra analysis of the
sleep electroencephalography in narcoleptic patients. SleepMed. 16, 1516–1527.
doi: 10.1016/j.sleep.2015.09.005
Correa, F., Wolfson, M. L., Valchi, P., Aisemberg, J., and Franchi, A. M. (2016).
Endocannabinoid system and pregnancy. Reproduction 152, R191–R200.
doi: 10.1530/rep-16-0167
Corsi-Cabrera, M., Pérez-Garci, E., Del Rio-Portilla, Y., Ugalde, E., and Guevara,
M. A. (2001). EEG bands during wakefulness, slow-wave, and paradoxical
sleep as a result of principal component analysis in the rat. Sleep 24, 374–380.
doi: 10.1093/sleep/24.4.374
de Lago, E., Petrosino, S., Valenti, M., Morera, E., Ortega-Gutierrez, S., Fernandez-
Ruiz, J., et al. (2005). Effect of repeated systemic administration of selective
inhibitors of endocannabinoid inactivation on rat brain endocannabinoid
levels. Biochem. Pharmacol. 70, 446–452. doi: 10.1016/j.bcp.2005.
05.011
de Novellis, V., Palazzo, E., Rossi, F., De Petrocellis, L., Petrosino, S., Guida, F., et al.
(2008). The analgesic effect of N-arachidonoyl-serotonin, a FAAH inhibitor and
TRPV1 receptor antagonist, associated with changes in rostral ventromedial
medulla and locus coeruleus cell activity in rats. Neuropharmacology 55,
1105–1113. doi: 10.1016/j.neuropharm.2008.06.023
Di Marzo, V., and De Petrocellis, L. (2012). Why do cannabinoid receptors have
more than one endogenous ligand? Philos. Trans. R. Soc. Lond. B Biol. Sci. 367,
3216–3228. doi: 10.1098/rstb.2011.0382
Di Marzo, V., and Piscitelli, F. (2015). The endocannabinoid system and
its modulation by phytocannabinoids. Neurotherapeutics 12, 692–698.
doi: 10.1007/s13311-015-0374-6
Doenni, V. M., Gray, J. M., Song, C. M., Patel, S., Hill, M. N., and Pittman, Q. J.
(2016). Deficient adolescent social behavior following early-life inflammation is
ameliorated by augmentation of anandamide signaling. Brain Behav. Immun.
58, 237–247. doi: 10.1016/j.bbi.2016.07.152
Dos Anjos-Garcia, T., Ullah, F., Falconi-Sobrinho, L. L., and Coimbra, N. C.
(2017). CB1 cannabinoid receptor-mediated anandamide signalling reduces
the defensive behaviour evoked through GABAA receptor blockade in the
dorsomedial division of the ventromedial hypothalamus. Neuropharmacology
113, 156–166. doi: 10.1016/j.neuropharm.2016.04.003
Fakhoury, M. (2017). Role of the endocannabinoid system in the pathophysiology
of schizophrenia. Mol. Neurobiol. 54, 768–778. doi: 10.1007/s12035-016-9697-5
Fitzpatrick, J. K., and Downer, E. J. (2017). Toll-like receptor signalling as a
cannabinoid target in multiple sclerosis. Neuropharmacology 113, 618–626.
doi: 10.1016/j.neuropharm.2016.04.009
Franken, P., Dijk, D. J., Tobler, I., and Borbély, A. A. (1991). Sleep deprivation in
rats: effects on EEG power spectra, vigilance states, and cortical temperature.
Am. J. Physiol. 261, R198–R208.
Gold, P. E., Countryman, R. A., Dukala, D., and Chang, Q. (2011). Acetylcholine
release in the hippocampus and prelimbic cortex during acquisition of a socially
transmitted food preference. Neurobiol. Learn. Mem. 96, 498–503. doi: 10.1016/
j.nlm.2011.08.004
Grupe, M., Paolone, G., Jensen, A. A., Sandager-Nielsen, K., Sarter, M., and
Grunnet, M. (2013). Selective potentiation of (alpha4)3(beta2)2 nicotinic
acetylcholine receptors augments amplitudes of prefrontal acetylcholine- and
nicotine-evoked glutamatergic transients in rats. Biochem. Pharmacol. 86,
1487–1496. doi: 10.1016/j.bcp.2013.09.005
Herrera-Solis, A., Vasquez, K. G., and Prospero-Garcia, O. (2010). Acute and
subchronic administration of anandamide or oleamide increases REM sleep
in rats. Pharmacol. Biochem. Behav. 95, 106–112. doi: 10.1016/j.pbb.2009.
12.014
Huang, W. J., Chen, W. W., and Zhang, X. (2016). Endocannabinoid system: role
in depression, reward and pain control (Review). Mol. Med. Rep. 14, 2899–2903.
doi: 10.3892/mmr.2016.5585
Imperatori, C., Della Marca, G., Brunetti, R., Carbone, G. A., Massullo, C., Valenti,
E. M., et al. (2016). Default mode network alterations in alexithymia: an EEG
power spectra and connectivity study. Sci Rep. 6:36653. doi: 10.1038/srep36653
Janssen, F. J., and van der Stelt, M. (2016). Inhibitors of diacylglycerol lipases
in neurodegenerative and metabolic disorders. Bioorg. Med. Chem. Lett. 26,
3831–3837. doi: 10.1016/j.bmcl.2016.06.076
Jing, W., Wang, Y., Fang, G., Chen, M., Xue, M., Guo, D., et al. (2016). EEG bands
of wakeful rest, slow-wave and rapid-eye-movement sleep at different brain
areas in rats. Front. Comput. Neurosci. 10:79. doi: 10.3389/fncom.2016.00079
John, C. S., and Currie, P. J. (2012). N-arachidonoyl-serotonin in the basolateral
amygdala increases anxiolytic behavior in the elevated plus maze. Behav. Brain
Res. 233, 382–388. doi: 10.1016/j.bbr.2012.05.025
Keith, J. M., Jones, W. M., Tichenor, M., Liu, J., Seierstad, M., Palmer, J. A., et al.
(2015). Preclinical characterization of the FAAH inhibitor JNJ-42165279. ACS
Med. Chem. Lett. 6, 1204–1208. doi: 10.1021/acsmedchemlett.5b00353
Kendall, D. A., and Yudowski, G. A. (2016). Cannabinoid receptors in the central
nervous system: their signaling and roles in disease. Front. Cell Neurosci. 10:294.
doi: 10.3389/fncel.2016.00294
Kim, D. (2012). Practical use and risk of modafinil, a novel waking drug. Environ.
Health Toxicol. 27, e2012007. doi: 10.5620/eht.2012.27.e2012007
Kirkedal, C., Wegener, G., Moreira, F., Joca, S. R., and Liebenberg, N. (2016).
A dual inhibitor of FAAH and TRPV1 channels shows dose-dependent effect
on depression-like behaviour in rats. Acta Neuropsychiatr. 12, 1–6. doi: 10.1017/
neu.2016.68
Kruk-Slomka, M., Dzik, A., Budzynska, B., and Biala, G. (2016). Endocannabinoid
system: the direct and indirect involvement in the memory and learning
processes-a short review. Mol. Neurobiol. doi: 10.1007/s12035-016-0313-5
[Epub ahead of print].
Lauria, S., Casati, S., and Ciuffreda, P. (2015). Synthesis and characterization of
a new fluorogenic substrate for monoacylglycerol lipase and application to
inhibition studies. Anal. Bioanal. Chem. 407, 8163–8167. doi: 10.1007/s00216-
015-8991-9
Frontiers in Molecular Neuroscience | www.frontiersin.org 19 May 2017 | Volume 10 | Article 152
fnmol-10-00152 May 26, 2017 Time: 15:43 # 20
Murillo-Rodríguez et al. Injections of N-Arachidonoyl-Serotonin (AA-5-HT) Increase Sleep
Lazarus, M., Chen, J. F., Urade, Y., and Huang, Z. L. (2013). Role of the basal ganglia
in the control of sleep and wakefulness. Curr. Opin. Neurobiol. 23, 780–785.
doi: 10.1016/j.conb.2013.02.001
Lazarus, M., Huang, Z. L., Lu, J., Urade, Y., and Chen, J. F. (2012). How do
the basal ganglia regulate sleep-wake behavior? Trends Neurosci. 35, 723–732.
doi: 10.1016/j.tins.2012.07.001
Leung, K., Elmes, M. W., Glaser, S. T., Deutsch, D. G., and Kaczocha, M. (2013).
Role of FAAH-like anandamide transporter in anandamide inactivation. PLoS
ONE 8:e79355. doi: 10.1371/journal.pone.0079355
Ligresti, A., De Petrocellis, L., and Di Marzo, V. (2016). From phytocannabinoids
to cannabinoid receptors and endocannabinoids: pleiotropic physiological and
pathological roles through complex pharmacology. Physiol. Rev. 96, 1593–1659.
doi: 10.1152/physrev.00002.2016
Liu, Z., Wang, Y., Cai, L., Li, Y., Chen, B., Dong, Y., et al. (2016). Prefrontal
cortex to accumbens projections in sleep regulation of reward. J. Neurosci. 36,
7897–7910. doi: 10.1523/JNEUROSCI.0347-16.2016
Lodola, A., Castelli, R., Mor, M., and Rivara, S. (2015). Fatty acid amide hydrolase
inhibitors: a patent review (2009-2014). Expert Opin. Ther. Pat. 25, 1247–1266.
doi: 10.1517/13543776.2015.1067683
Lowin, T., and Straub, R. H. (2015). Cannabinoid-based drugs targeting CB1 and
TRPV1, the sympathetic nervous system, and arthritis. Arthritis Res. Ther. 17,
226. doi: 10.1186/s13075-015-0743-x
Lu, H. C., and Mackie, K. (2016). An introduction to the endogenous cannabinoid
system. Biol. Psychiatry 79, 516–525. doi: 10.1016/j.biopsych.2015.07.028
Mallipeddi, S., Janero, D. R., Zvonok, N., and Makriyannis, A. (2017). Functional
selectivity at G-protein coupled receptors: advancing cannabinoid receptors
as drug targets. Biochem. Pharmacol. 128, 1–11. doi: 10.1016/j.bcp.2016.
11.014
Marinelli, S., Pascucci, T., Bernardi, G., Puglisi-Allegra, S., and Mercuri, N. B.
(2005). Activation of TRPV1 in the VTA excites dopaminergic neurons
and increases chemical- and noxious-induced dopamine release in the
nucleus accumbens. Neuropsychopharmacology 30, 864–870. doi: 10.1038/sj.
npp.1300615
Mazzucchelli, I., Rapetti, M., Fattore, C., Franco, V., Gatti, G., and Perucca, E.
(2011). Development and validation of an HPLC-UV detection assay for the
determination of rufinamide in human plasma and saliva. Anal. Bioanal. Chem.
401, 1013–1021. doi: 10.1007/s00216-011-5126-9
Micale, V., Cristino, L., Tamburella, A., Petrosino, S., Leggio, G. M., Drago, F.,
et al. (2009). Anxiolytic effects in mice of a dual blocker of fatty acid
amide hydrolase and transient receptor potential vanilloid type-1 channels.
Neuropsychopharmacology 34, 593–606. doi: 10.1038/npp.2008.98
Mijangos-Moreno, S., Poot-Ake, A., Arankowsky-Sandoval, G., and Murillo-
Rodríguez, E. (2014). Intrahypothalamic injection of cannabidiol increases the
extracellular levels of adenosine in nucleus accumbens in rats. Neurosci. Res. 84,
60–63. doi: 10.1016/j.neures.2014.04.006
Mijangos-Moreno, S., Poot-Ake, A., Guzman, K., Arankowsky-Sandoval, G., Arias-
Carrion, O., Zaldivar-Rae, J., et al. (2016). Sleep and neurochemical modulation
by the nuclear peroxisome proliferator-activated receptor alpha (PPAR-alpha)
in rat. Neurosci. Res. 105, 65–69. doi: 10.1016/j.neures.2015.09.005
Mijangos-Moreno, S., Poot-Aké, A., Sarro-Ramírez, A., Jiménez-Moreno, R.,
Pacheco-Pantoja, E., Aquino-Hernández, P., et al. (2015). Circadian and sleep-
deprivation variations of monophosphorylated MAP-Kinase in hypothalamus
and pons of rats. Biol. Rhythm Res. 46, 763–770. doi: 10.1080/09291016.2015.
1052651
Murillo-Rodríguez, E., Blanco-Centurion, C., Gerashchenko, D., Salin-Pascual,
R. J., and Shiromani, P. J. (2004). The diurnal rhythm of adenosine levels
in the basal forebrain of young and old rats. Neuroscience 123, 361–370.
doi: 10.1016/j.neuroscience.2003.09.015
Murillo-Rodríguez, E., Blanco-Centurion, C., Sanchez, C., Piomelli, D., and
Shiromani, P. J. (2003). Anandamide enhances extracellular levels of adenosine
and induces sleep: an in vivo microdialysis study. Sleep 26, 943–947.
doi: 10.1093/sleep/26.8.943
Murillo-Rodríguez, E., Cabeza, R., Mendez-Diaz, M., Navarro, L., and Prospero-
Garcia, O. (2001). Anandamide-induced sleep is blocked by SR141716A, a CB1
receptor antagonist and by U73122, a phospholipase C inhibitor. Neuroreport
12, 2131–2136. doi: 10.1097/00001756-200107200-00018
Murillo-Rodríguez, E., Haro, R., Palomero-Rivero, M., Millan-Aldaco, D., and
Drucker-Colin, R. (2007a). Modafinil enhances extracellular levels of dopamine
in the nucleus accumbens and increases wakefulness in rats. Behav. Brain Res.
176, 353–357.
Murillo-Rodríguez, E., Machado, S., Rocha, N. B., Budde, H., Yuan, T. F.,
and Arias-Carrion, O. (2016). Revealing the role of the endocannabinoid
system modulators, SR141716A, URB597 and VDM-11, in sleep homeostasis.
Neuroscience 339, 433–449. doi: 10.1016/j.neuroscience.2016.10.011
Murillo-Rodríguez, E., Millan-Aldaco, D., Di Marzo, V., and Drucker-Colin, R.
(2008a). The anandamide membrane transporter inhibitor, VDM-11,
modulates sleep and c-Fos expression in the rat brain. Neuroscience 157,
1–11. doi: 10.1016/j.neuroscience.2008.08.056
Murillo-Rodríguez, E., Millan-Aldaco, D., Palomero-Rivero, M., Mechoulam, R.,
and Drucker-Colin, R. (2008b). The nonpsychoactive Cannabis constituent
cannabidiol is a wake-inducing agent. Behav. Neurosci. 122, 1378–1382.
doi: 10.1037/a0013278
Murillo-Rodríguez, E., Millan-Aldaco, D., Palomero-Rivero, M., Mechoulam, R.,
and Drucker-Colin, R. (2006). Cannabidiol, a constituent of Cannabis sativa,
modulates sleep in rats. FEBS Lett. 580, 4337–4345. doi: 10.1016/j.febslet.2006.
04.102
Murillo-Rodríguez, E., Palomero-Rivero, M., Millan-Aldaco, D., Arias-Carrion, O.,
and Drucker-Colin, R. (2011a). Administration of URB597, oleoylethanolamide
or palmitoylethanolamide increases waking and dopamine in rats. PLoS ONE
6:e20766. doi: 10.1371/journal.pone.0020766
Murillo-Rodríguez, E., Palomero-Rivero, M., Millan-Aldaco, D., and Di Marzo, V.
(2013). The administration of endocannabinoid uptake inhibitors OMDM-2 or
VDM-11 promotes sleep and decreases extracellular levels of dopamine in rats.
Physiol. Behav. 109, 88–95. doi: 10.1016/j.physbeh.2012.11.007
Murillo-Rodríguez, E., Palomero-Rivero, M., Millan-Aldaco, D., Mechoulam, R.,
and Drucker-Colin, R. (2011b). Effects on sleep and dopamine levels of
microdialysis perfusion of cannabidiol into the lateral hypothalamus of rats. Life
Sci. 88, 504–511. doi: 10.1016/j.lfs.2011.01.013
Murillo-Rodríguez, E., Sanchez-Alavez, M., Navarro, L., Martinez-Gonzalez, D.,
Drucker-Colin, R., and Prospero-Garcia, O. (1998). Anandamide modulates
sleep and memory in rats. Brain Res. 812, 270–274. doi: 10.1016/S0006-8993(98)
00969-X
Murillo-Rodríguez, E., Vazquez-Luis, E., Millan-Aldaco, D., Haro, R., and Drucker-
Colin, R. (2008c). Promoting of wakefulness by administrations of modafinil
into anterior hypothalamus and into the pedunculopontine tegmental
nucleus in rats. Neurosci. Lett. 436, 283–287. doi: 10.1016/j.neulet.2008.
03.048
Murillo-Rodríguez, E., Vazquez, E., Millan-Aldaco, D., Palomero-Rivero, M., and
Drucker-Colin, R. (2007b). Effects of the fatty acid amide hydrolase inhibitor
URB597 on the sleep-wake cycle, c-Fos expression and dopamine levels of the
rat. Eur. J. Pharmacol. 562, 82–91.
Navarria, A., Tamburella, A., Iannotti, F. A., Micale, V., Camillieri, G., Gozzo, L.,
et al. (2014). The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin
reverses the behavioral despair induced by stress in rats and modulates the
HPA-axis. Pharmacol. Res. 87, 151–159. doi: 10.1016/j.phrs.2014.04.014
Nicolussi, S., and Gertsch, J. (2015). Endocannabinoid transport revisited. Vitam
Horm. 98, 441–485. doi: 10.1016/bs.vh.2014.12.011
Nimczick, M., and Decker, M. (2015). New approaches in the design
and development of cannabinoid receptor ligands: multifunctional and
bivalent compounds. ChemMedChem. 10, 773–786. doi: 10.1002/cmdc.20150
0041
Palazzo, E., Luongo, L., Novellis, V., Rossi, F., and Maione, S. (2010). The role of
cannabinoid receptors in the descending modulation of pain. Pharmaceuticals
3, 2661–2673. doi: 10.3390/ph3082661
Panlilio, L. V., Thorndike, E. B., Nikas, S. P., Alapafuja, S. O., Bandiera, T., Cravatt,
B. F., et al. (2016). Effects of fatty acid amide hydrolase (FAAH) inhibitors on
working memory in rats. Psychopharmacology 233, 1879–1888. doi: 10.1007/
s00213-015-4140-6
Pava, M. J., Den Hartog, C. R., Blanco-Centurion, C., Shiromani, P. J., and
Woodward, J. J. (2014). Endocannabinoid modulation of cortical up-states and
NREM sleep. PLoS ONE 9:e88672. doi: 10.1371/journal.pone.0088672
Pava, M. J., Makriyannis, A., and Lovinger, D. M. (2016). Endocannabinoid
signaling regulates sleep stability. PLoS ONE 11:e0152473. doi: 10.1371/journal.
pone.0152473
Paxinos, G., and Watson, C. (2005). The Rat Brain in Stereotaxic Coordinates. San
Diego, CA: Academic Press.
Frontiers in Molecular Neuroscience | www.frontiersin.org 20 May 2017 | Volume 10 | Article 152
fnmol-10-00152 May 26, 2017 Time: 15:43 # 21
Murillo-Rodríguez et al. Injections of N-Arachidonoyl-Serotonin (AA-5-HT) Increase Sleep
Pember, S. O., Mejia, G. L., Price, T. J., and Pasteris, R. J. (2016). Piperidinyl
thiazole isoxazolines: a new series of highly potent, slowly reversible FAAH
inhibitors with analgesic properties. Bioorg. Med. Chem. Lett. 26, 2965–2973.
doi: 10.1016/j.bmcl.2016.02.061
Piomelli, D. (2014). More surprises lying ahead. The endocannabinoids keep us
guessing. Neuropharmacology 76(Pt B), 228–234. doi: 10.1016/j.neuropharm.
2013.07.026
Porkka-Heiskanen, T., Strecker, R. E., and Mccarley, R. W. (2000). Brain site-
specificity of extracellular adenosine concentration changes during sleep
deprivation and spontaneous sleep: an in vivo microdialysis study. Neuroscience
99, 507–517. doi: 10.1016/S0306-4522(00)00220-7
Qiu, M. H., Liu, W., Qu, W. M., Urade, Y., Lu, J., and Huang, Z. L. (2012). The role
of nucleus accumbens core/shell in sleep-wake regulation and their involvement
in modafinil-induced arousal. PLoS ONE 7:e45471. doi: 10.1371/journal.pone.
0045471
Rueda-Orozco, P. E., Soria-Gomez, E., Montes-Rodriguez, C. J., Perez-
Morales, M., and Prospero-Garcia, O. (2010). Intrahippocampal administration
of anandamide increases REM sleep. Neurosci. Lett. 473, 158–162. doi: 10.1016/
j.neulet.2010.02.044
Santucci, V., Storme, J. J., Soubrie, P., and Le Fur, G. (1996). Arousal-enhancing
properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as
assessed by electroencephalographic spectral and sleep-waking cycle analysis.
Life Sci. 58, L103–L110. doi: 10.1016/0024-3205(95)02319-4
Sartim, A. G., Moreira, F. A., and Joca, S. R. (2017). Involvement of CB1
and TRPV1 receptors located in the ventral medial prefrontal cortex in the
modulation of stress coping behavior. Neuroscience 340, 126–134. doi: 10.1016/
j.neuroscience.2016.10.031
Sartori, T., Seigi Murakami, F., Pinheiro Cruz, A., and Machado De Campos, A.
(2008). Development and validation of a fast RP-HPLC method for
determination of methotrexate entrapment efficiency in polymeric
nanocapsules. J. Chromatogr. Sci. 46, 505–509. doi: 10.1093/chromsci/46.6.505
Scammell, T. E., Estabrooke, I. V., Mccarthy, M. T., Chemelli, R. M.,
Yanagisawa, M., Miller, M. S., et al. (2000). Hypothalamic arousal regions are
activated during modafinil-induced wakefulness. J. Neurosci. 20, 8620–8628.
Starowicz, K., Makuch, W., Osikowicz, M., Piscitelli, F., Petrosino, S., Di Marzo, V.,
et al. (2012). Spinal anandamide produces analgesia in neuropathic rats:
possible CB(1)- and TRPV1-mediated mechanisms. Neuropharmacology 62,
1746–1755. doi: 10.1016/j.neuropharm.2011.11.021
Sukhal, S., Khalid, M., and Tulaimat, A. (2015). Effect of wakefulness-promoting
agents on sleepiness in patients with sleep apnea treated with CPAP: a
meta-analysis. J. Clin. Sleep Med. 11, 1179–1186. doi: 10.5664/jcsm.5096
Sun, L., Tai, L., Qiu, Q., Mitchell, R., Fleetwood-Walker, S., Joosten, E. A.,
et al. (2017). Endocannabinoid activation of CB1 receptors contributes to
long-lasting reversal of neuropathic pain by repetitive spinal cord stimulation.
Eur. J. Pain 21, 804–814. doi: 10.1002/ejp.983
Sunduru, N., Svensson, M., Cipriano, M., Marwaha, S., Andersson, C. D.,
Svensson, R., et al. (2017). N-aryl 2-aryloxyacetamides as a new class of fatty acid
amide hydrolase (FAAH) inhibitors. J. Enzyme Inhib. Med. Chem. 32, 513–521.
doi: 10.1080/14756366.2016.1265520
Svetnik, V., Snyder, E. S., Ma, J., Tao, P., Lines, C., and Herring, W. J. (2017). EEG
spectral analysis of NREM sleep in a large sample of patients with insomnia and
good sleepers: effects of age, sex and part of the night. J. Sleep Res. 26, 92–104.
doi: 10.1111/jsr.12448
Tobler, I., and Borbély, A. A. (1990). The effect of 3-h and 6-h sleep deprivation
on sleep and EEG spectra of the rat. Behav. Brain Res. 36, 73–78. doi: 10.1016/
0166-4328(90)90161-7
Tong, J., Mizrahi, R., Houle, S., Kish, S. J., Boileau, I., Nobrega, J., et al. (2016).
Inhibition of fatty acid amide hydrolase by BIA 10-2474 in rat brain. J. Cereb.
Blood Flow Metab. doi: 10.1177/0271678X16668890
Tóth, A., Blumberg, P. M., and Boczan, J. (2009). Anandamide and the vanilloid
receptor (TRPV1). Vitam Horm. 81, 389–419. doi: 10.1016/S0083-6729(09)
81015-7
Tuo, W., Leleu-Chavain, N., Barczyk, A., Renault, N., Lemaire, L., Chavatte, P.,
et al. (2016). Design, synthesis and biological evaluation of potent FAAH
inhibitors. Bioorg. Med. Chem. Lett. 26, 2701–2705. doi: 10.1016/j.bmcl.2016.
04.004
Vilela, L. R., Medeiros, D. C., de Oliveira, A. C., Moraes, M. F., and Moreira, F. A.
(2014). Anticonvulsant effects of N-arachidonoyl-serotonin, a dual fatty acid
amide hydrolase. (enzyme )and transient receptor potential vanilloid type-1
(TRPV1) channel blocker, on experimental seizures: the roles of cannabinoid
CB1 receptors and TRPV1 channels. Basic Clin. Pharmacol. Toxicol. 115,
330–334. doi: 10.1111/bcpt.12232
Wang, D., Bai, X. X., Williams, S. C., Hua, S. C., Kim, J. W., Marshall, N. S., et al.
(2015). Modafinil increases awake EEG activation and improves performance in
obstructive sleep apnea during continuous positive airway pressure withdrawal.
Sleep 38, 1297–1303. doi: 10.5665/sleep.4912
Wilkerson, J. L., Ghosh, S., Mustafa, M., Abdullah, R. A., Niphakis, M. J.,
Cabrera, R., et al. (2017). The endocannabinoid hydrolysis inhibitor
SA-57: intrinsic antinociceptive effects, augmented morphine-induced
antinociception, and attenuated heroin seeking behavior in mice.
Neuropharmacology 114, 156–167. doi: 10.1016/j.neuropharm.2016.
11.015
Winkler, K., Ramer, R., Dithmer, S., Ivanov, I., Merkord, J., and Hinz, B. (2016).
Fatty acid amide hydrolase inhibitors confer anti-invasive and antimetastatic
effects on lung cancer cells. Oncotarget 7, 15047–15064. doi: 10.18632/
oncotarget.7592
Wollank, Y., Ramer, R., Ivanov, I., Salamon, A., Peters, K., and Hinz, B. (2015).
Inhibition of FAAH confers increased stem cell migration via PPARalpha.
J. Lipid Res. 56, 1947–1960. doi: 10.1194/jlr.M061473
Yuan, D., Wu, Z., and Wang, Y. (2016). Evolution of the diacylglycerol lipases.
Prog. Lipid Res. 64, 85–97. doi: 10.1016/j.plipres.2016.08.004
Zahov, S., Garzinsky, D., Hanekamp, W., and Lehr, M. (2017). 1-Heteroarylpropan-
2-ones as inhibitors of fatty acid amide hydrolase: studies on structure-activity
relationships and metabolic stability. Bioorg. Med. Chem. 25, 825–837. doi:
10.1016/j.bmc.2016.11.025
Zhang, J. P., Xu, Q., Yuan, X. S., Cherasse, Y., Schiffmann, S. N., De Kerchove
D’exaerde, A., et al. (2013). Projections of nucleus accumbens adenosine A2A
receptor neurons in the mouse brain and their implications in mediating
sleep-wake regulation. Front. Neuroanat. 7:43. doi: 10.3389/fnana.2013.
00043
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Murillo-Rodríguez, Di Marzo, Machado, Rocha, Veras, Neto,
Budde, Arias-Carrión and Arankowsky-Sandoval. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Molecular Neuroscience | www.frontiersin.org 21 May 2017 | Volume 10 | Article 152
